<?xml version="1.0" encoding="UTF-8"?>
<p>Drug repositioning has played a large role in this case, and educated guesses were made to determine the best combination of existing antiviral therapies to treat the novel disease. In the early stages of the COVID-19 outbreak, doctors in Bangkok, Thailand, administered a combination of antiviral drugs Oseltamivir and Lopinavir/Ritonavir for Influenza and HIV to a Chinese woman who was infected with COVID-19, improving her condition shortly after [
 <xref rid="B86-viruses-12-01058" ref-type="bibr">86</xref>]. Additionally, potential drugs such as the nucleoside analogue, Remdesivir peptide (EK1), RNA synthesis inhibitors (TDF, 3TC) and anti-inflammatory drugs have been suggested as potential drugs to be used in the treatment of COVID-19 patients in the time before a specific therapy is developed [
 <xref rid="B87-viruses-12-01058" ref-type="bibr">87</xref>]. In addition, there have been many cases that followed which are now exploring the potential of antiviral drugs for other viral diseases to be used for COVID-19. Two HIV protease inhibitors, namely, Ritonavir and ASC09, are currently underway in clinical trials to treat COVID-19 [
 <xref rid="B88-viruses-12-01058" ref-type="bibr">88</xref>]. Simultaneously, BrightGene Bio-Medical Technology, a Suzhou-based company, has announced that they will be manufacturing Remdesivir (GS-5734), an abandoned drug which was initially developed to treat Ebola virus, as an antiviral drug against COVID-19 [
 <xref rid="B88-viruses-12-01058" ref-type="bibr">88</xref>]. 
</p>
